$RLAY
Relay Therapeutics, Inc.

2024 Q4 Form 10-Q Financial Statement

#000095017024122332 Filed on November 06, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $19.75M
YoY Change 6.81%
% of Gross Profit
Research & Development $76.62M
YoY Change -5.98%
% of Gross Profit
Depreciation & Amortization $1.367M
YoY Change 0.51%
% of Gross Profit
Operating Expenses $96.37M
YoY Change -2.44%
Operating Profit -$96.37M
YoY Change 30.98%
Interest Expense $8.274M
YoY Change 5.4%
% of Operating Profit
Other Income/Expense, Net $8.264M
YoY Change 5.37%
Pretax Income -$88.11M
YoY Change 34.04%
Income Tax
% Of Pretax Income
Net Earnings -$88.11M
YoY Change 34.03%
Net Earnings / Revenue
Basic Earnings Per Share -$0.63
Diluted Earnings Per Share -$0.63
COMMON SHARES
Basic Shares Outstanding 167.4M 133.9M
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $839.6M
YoY Change 3.58%
Cash & Equivalents $152.4M
Short-Term Investments $687.3M
Other Short-Term Assets $6.795M
YoY Change 84.75%
Inventory
Prepaid Expenses $18.73M
Receivables
Other Receivables
Total Short-Term Assets $865.1M
YoY Change 4.01%
LONG-TERM ASSETS
Property, Plant & Equipment $7.210M
YoY Change -32.62%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.119M
YoY Change -21.52%
Total Long-Term Assets $64.99M
YoY Change -13.54%
TOTAL ASSETS
Total Short-Term Assets $865.1M
Total Long-Term Assets $64.99M
Total Assets $930.1M
YoY Change 2.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.867M
YoY Change -48.57%
Accrued Expenses $33.22M
YoY Change 5.49%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $46.97M
YoY Change -7.45%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $44.29M
YoY Change -43.08%
Total Long-Term Liabilities $44.29M
YoY Change -43.08%
TOTAL LIABILITIES
Total Short-Term Liabilities $46.97M
Total Long-Term Liabilities $44.29M
Total Liabilities $91.25M
YoY Change -29.03%
SHAREHOLDERS EQUITY
Retained Earnings -$1.662B
YoY Change 27.87%
Common Stock $167.0K
YoY Change 35.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $838.9M
YoY Change
Total Liabilities & Shareholders Equity $930.1M
YoY Change 2.55%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$88.11M
YoY Change 34.03%
Depreciation, Depletion And Amortization $1.367M
YoY Change 0.51%
Cash From Operating Activities -$75.08M
YoY Change -0.42%
INVESTING ACTIVITIES
Capital Expenditures $227.0K
YoY Change -61.53%
Acquisitions
YoY Change
Other Investing Activities -$125.9M
YoY Change -275.03%
Cash From Investing Activities -$126.2M
YoY Change -276.77%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 218.9M
YoY Change 2213.84%
NET CHANGE
Cash From Operating Activities -75.08M
Cash From Investing Activities -126.2M
Cash From Financing Activities 218.9M
Net Change In Cash 17.64M
YoY Change 224.94%
FREE CASH FLOW
Cash From Operating Activities -$75.08M
Capital Expenditures $227.0K
Free Cash Flow -$75.31M
YoY Change -0.89%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001812364
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#LicenseAndServiceMember
CY2023Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#LicenseAndServiceMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#LicenseAndServiceMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#LicenseAndServiceMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39385
dei Entity Registrant Name
EntityRegistrantName
RELAY THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-3923475
dei Entity Address Address Line1
EntityAddressAddressLine1
399 Binney Street
dei Entity Address Address Line2
EntityAddressAddressLine2
2nd Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02142
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
370-8837
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
RLAY
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
167382958
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
152357000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
143736000
CY2024Q3 us-gaap Investments
Investments
687252000
CY2023Q4 us-gaap Investments
Investments
606350000
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
18725000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
16702000
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
6795000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
3315000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
865129000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
770103000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7210000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10901000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
53357000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
57969000
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2119000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2707000
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2300000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2300000
CY2024Q3 us-gaap Assets
Assets
930115000
CY2023Q4 us-gaap Assets
Assets
843980000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
6867000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9211000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
33216000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14890000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5529000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4964000
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1356000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1204000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
46968000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
30269000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
44286000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
48502000
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
13206000
CY2024Q3 us-gaap Liabilities
Liabilities
91254000
CY2023Q4 us-gaap Liabilities
Liabilities
91977000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
166886661
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
166886661
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
127462409
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
127462409
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
167000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
127000
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2498471000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2152654000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2509000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-196000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1662286000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1400582000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
838861000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
752003000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
930115000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
843980000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25202000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10007000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25547000
CY2023Q3 us-gaap Revenues
Revenues
25202000
us-gaap Revenues
Revenues
10007000
us-gaap Revenues
Revenues
25547000
CY2024Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
76619000
CY2023Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
81494000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
251014000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
252522000
CY2024Q3 rlay Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
0
CY2023Q3 rlay Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
-1200000
rlay Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
-13206000
rlay Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
-4355000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19750000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18485000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
59688000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
58184000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
96369000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
98779000
us-gaap Operating Expenses
OperatingExpenses
297496000
us-gaap Operating Expenses
OperatingExpenses
306351000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-96369000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-73577000
us-gaap Operating Income Loss
OperatingIncomeLoss
-287489000
us-gaap Operating Income Loss
OperatingIncomeLoss
-280804000
CY2024Q3 us-gaap Interest Income Other
InterestIncomeOther
8274000
CY2023Q3 us-gaap Interest Income Other
InterestIncomeOther
7845000
us-gaap Interest Income Other
InterestIncomeOther
25772000
us-gaap Interest Income Other
InterestIncomeOther
22345000
CY2024Q3 rlay Other Income Expense
OtherIncomeExpense
-10000
CY2023Q3 rlay Other Income Expense
OtherIncomeExpense
-2000
rlay Other Income Expense
OtherIncomeExpense
13000
rlay Other Income Expense
OtherIncomeExpense
-19000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
8264000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7843000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
25785000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
22326000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-88105000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-65734000
us-gaap Net Income Loss
NetIncomeLoss
-261704000
us-gaap Net Income Loss
NetIncomeLoss
-258478000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.63
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.63
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.94
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.94
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.12
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.12
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
140229056
CY2024Q3 rlay Weighted Average Number Of Shares Outstanding Diluted
WeightedAverageNumberOfSharesOutstandingDiluted
140229056
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
122231255
CY2023Q3 rlay Weighted Average Number Of Shares Outstanding Diluted
WeightedAverageNumberOfSharesOutstandingDiluted
122231255
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
134651728
rlay Weighted Average Number Of Shares Outstanding Diluted
WeightedAverageNumberOfSharesOutstandingDiluted
134651728
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
121843116
rlay Weighted Average Number Of Shares Outstanding Diluted
WeightedAverageNumberOfSharesOutstandingDiluted
121843116
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
3849000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
2695000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
2705000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
7034000
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
3849000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
2695000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
2705000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
7034000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-84256000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-63039000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-258999000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-251444000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
752003000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1187000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
27188000
CY2024Q1 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-962000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-81387000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
745764000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
413000
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1129000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
26832000
CY2024Q2 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-182000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
681744000
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
732000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
22484000
CY2024Q3 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
3849000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-88105000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
838861000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
950218000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1297000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
21518000
CY2023Q1 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
4618000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-94239000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
883412000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
453000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1627000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
23411000
CY2023Q2 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-279000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-98505000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
810119000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
95000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
21835000
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
2695000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-65734000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
778373000
us-gaap Net Income Loss
NetIncomeLoss
-261704000
us-gaap Net Income Loss
NetIncomeLoss
-258478000
us-gaap Share Based Compensation
ShareBasedCompensation
76504000
us-gaap Share Based Compensation
ShareBasedCompensation
66764000
us-gaap Depreciation
Depreciation
4130000
us-gaap Depreciation
Depreciation
3894000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
10134000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
7094000
rlay Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
-13206000
rlay Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
-4355000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-95000
us-gaap Increase Decrease In Commodity Contract Assets And Liabilities
IncreaseDecreaseInCommodityContractAssetsAndLiabilities
-4913000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
5503000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
5603000
rlay Increase Decrease In Operating Lease Assets And Liabilities Net
IncreaseDecreaseInOperatingLeaseAssetsAndLiabilitiesNet
-961000
rlay Increase Decrease In Operating Lease Assets And Liabilities Net
IncreaseDecreaseInOperatingLeaseAssetsAndLiabilitiesNet
-1159000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-993000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2980000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
18706000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-15427000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
24000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-191239000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-211128000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2018000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4008000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
575553000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
248727000
us-gaap Proceeds From Sale And Maturity Of Other Investments
ProceedsFromSaleAndMaturityOfOtherInvestments
507490000
us-gaap Proceeds From Sale And Maturity Of Other Investments
ProceedsFromSaleAndMaturityOfOtherInvestments
450691000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-70081000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
197956000
rlay Proceeds From Issuance Of Common Stock Through Private Placement Net
ProceedsFromIssuanceOfCommonStockThroughPrivatePlacementNet
29803000
rlay Proceeds From Issuance Of Common Stock Via At The Market Offerings Net
ProceedsFromIssuanceOfCommonStockViaAtTheMarketOfferingsNet
17932000
rlay Proceeds From Issuance Of Common Stock Via At The Market Offerings Net
ProceedsFromIssuanceOfCommonStockViaAtTheMarketOfferingsNet
9363000
rlay Proceeds From Issuance Of Common Stock Through Follow On Offering Net
ProceedsFromIssuanceOfCommonStockThroughFollowOnOfferingNet
218157000
rlay Proceeds From Issuance Of Common Stock Upon Exercise Of Stock Options
ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptions
2332000
rlay Proceeds From Issuance Of Common Stock Upon Exercise Of Stock Options
ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptions
1845000
rlay Proceeds From Issuance Of Common Stock Via Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockViaEmployeeStockPurchasePlan
1129000
rlay Proceeds From Issuance Of Common Stock Via Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockViaEmployeeStockPurchasePlan
1627000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
269353000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12835000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8033000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-337000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
146443000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
154372000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
154476000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
154035000
rlay Periodic Change To Additions Of Property And Equipment In Current Liabilities
PeriodicChangeToAdditionsOfPropertyAndEquipmentInCurrentLiabilities
-1579000
rlay Periodic Change To Additions Of Property And Equipment In Current Liabilities
PeriodicChangeToAdditionsOfPropertyAndEquipmentInCurrentLiabilities
-1047000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
152357000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
151328000
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
2119000
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
2707000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
154476000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
154035000
CY2024Q2 rlay Number Of New Discovery Stage Programs
NumberOfNewDiscoveryStagePrograms
3
CY2024Q2 rlay Number Of New Novel Programs
NumberOfNewNovelPrograms
2
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1700000000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the fair value of contingent milestone payments in connection with the acquisition of ZebiAI Therapeutics, Inc. ("ZebiAI"), the determination of the transaction price and standalone selling price of performance obligations under Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> ("ASC 606"), the accrual of research and development and manufacturing expenses, the valuation of equity instruments, and the incremental borrowing rate for determining operating lease assets and liabilities. Estimates are periodically reviewed in light of changes in circumstances, facts, and experience.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2024Q2 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
0
CY2023Q2 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
29223000
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
13206000
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
32378000
CY2024Q3 rlay Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Milestone Payments
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentMilestonePayments
0
CY2023Q3 rlay Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Milestone Payments
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentMilestonePayments
-1200000
rlay Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Milestone Payments
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentMilestonePayments
-8206000
rlay Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Milestone Payments
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentMilestonePayments
-4355000
CY2024Q3 rlay Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Earnout Payments
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentEarnoutPayments
0
rlay Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Earnout Payments
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentEarnoutPayments
-5000000
CY2023Q3 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
28023000
CY2023Q3 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
28023000
CY2024Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
684743000
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2807000
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
298000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
687252000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
606546000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
698000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
894000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
606350000
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
178009000
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
273000
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
48950000
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
25000
CY2024Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
226959000
CY2024Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
298000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
308981000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
578000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
64564000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
316000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
373545000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
894000
CY2024Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
46
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
70
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock entitles the stockholder to one vote on all matters submitted to a vote of the Company’s stockholders.
us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
22484000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
21835000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
76504000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
66764000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-88105000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-65734000
us-gaap Net Income Loss
NetIncomeLoss
-261704000
us-gaap Net Income Loss
NetIncomeLoss
-258478000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.63
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.63
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.94
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.94
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.12
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.12
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
140229056
CY2024Q3 rlay Weighted Average Number Of Shares Outstanding Diluted
WeightedAverageNumberOfSharesOutstandingDiluted
140229056
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
122231255
CY2023Q3 rlay Weighted Average Number Of Shares Outstanding Diluted
WeightedAverageNumberOfSharesOutstandingDiluted
122231255
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
134651728
rlay Weighted Average Number Of Shares Outstanding Diluted
WeightedAverageNumberOfSharesOutstandingDiluted
134651728
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
121843116
rlay Weighted Average Number Of Shares Outstanding Diluted
WeightedAverageNumberOfSharesOutstandingDiluted
121843116
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23949717
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23949717
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19494538
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19494538

Files In Submission

Name View Source Status
0000950170-24-122332-index-headers.html Edgar Link pending
0000950170-24-122332-index.html Edgar Link pending
0000950170-24-122332.txt Edgar Link pending
0000950170-24-122332-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rlay-20240930.htm Edgar Link pending
rlay-20240930.xsd Edgar Link pending
rlay-ex31_1.htm Edgar Link pending
rlay-ex31_2.htm Edgar Link pending
rlay-ex32_1.htm Edgar Link pending
Show.js Edgar Link pending
rlay-20240930_htm.xml Edgar Link completed